Cited by 1,296HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV Research and Treatment

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Open access

Marrazzo, Jeanne M., Ramjee, Gita, Richardson, Barbra A., Gomez, Kailazarid, Mgodi, Nyaradzo, Nair, Gonasagrie, Palanee, Thesla, Nakabiito, Clemensia, van der Straten, Ariane, Noguchi, Lisa, Hendrix, Craig W., Dai, James Y., Ganesh, Shayhana, Mkhize, Baningi, Taljaard, Marthinette, Parikh, Urvi M., Piper, Jeanna, Mâsse, Benoît, Grossman, Cynthia, Rooney, James, Schwartz, Jill L., Watts, Heather, Marzinke, Mark A., Hillier, Sharon L., McGowan, Ian M., Chirenje, Z. Mike·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1402269PMC PMC4341965

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimbabwe. HIV-1 testing was performed monthly, and plasma TFV levels were assessed quarterly. RESULTS: Of 12,320 women who were screened, 5029 were enrolled in the study. The rate of retention in the study was 91% during 5509 person-years of follow-up. A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-years. In the modified intention-to-treat analysis, the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21). In a random sample, TFV was detected in 30%, 29%, and 25% of available plasma samples from participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively. Independent predictors of TFV detection included being married, being older than 25 years of age, and being multiparous. Detection of TFV in plasma was negatively associated with characteristics predictive of HIV-1 acquisition. Elevations of serum creatinine levels were seen more frequently among participants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1.3% vs. 0.2%, P=0.004). We observed no significant differences in the frequencies of other adverse events. CONCLUSIONS: None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis. Adherence to study drugs was low. (Funded by the National Institutes of Health; VOICE ClinicalTrials.gov number, NCT00705679.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1402269

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citation
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
A Case-Cohort Design for Epidemiologic Cohort Studies and Disease Prevention Trials
Prentice, R. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.1 · Cited by 1,444
High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa
Tanser, F. C., Bärnighausen, T., Grapsa, E., Zaidi, J., & Newell, M. (2013) · Science · doi:10.1126/science.1228160 · Cited by 797
Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation
Liu, T. F., & Shafer, R. W. (2006) · Clinical Infectious Diseases · doi:10.1086/503914 · Cited by 661
Complex Surveys: A Guide to Analysis Using R
Lumley, T. (2010) · doi:10.1002/9780470580066 · Cited by 647

Flagged first, then by citations

Show all 19 references

Sorted by citations

Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., Sullivan, A. K., Clarke, A., Reeves, I., Schembri, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00056-2 · Cited by 1,878
Self-citation
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Molina, J., Capitant, C., Spire, B., Pialoux, G., Cotte, L., Charreau, I., Tremblay, C. L., Gall, J.-M. L., Cua, É., Pasquet, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506273 · Cited by 1,698
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations
Fonner, V. A., Dalglish, S. L., Kennedy, C. E., Baggaley, R. C., O’Reilly, K., Koechlin, F. M., Rodolph, M., Hodges-Mameletzis, I., & Grant, R. M. (2016) · AIDS · doi:10.1097/qad.0000000000001145 · Cited by 1,026
HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities
Kharsany, A. B. M., & Karim, Q. A. (2016) · The Open AIDS Journal · doi:10.2174/1874613601610010034 · Cited by 1,041
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Landovitz, R. J., Donnell, D. J., Clement, M. E., Hanscom, B. S., Cottle, L. M., Coelho, L. E., Cabello, R. L., Chariyalertsak, S., Dunne, E. F., Frank, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101016 · Cited by 934
Use of a vaginal ring containing dapivirine for HIV-1 prevention in women.
Baeten, J. M., Palanee-Phillips, T., Brown, E. R., Schwartz, K., Soto-Torres, L. E., Govender, V., Mgodi, N. M., Matovu Kiweewa, F., Nair, G., Mhlanga, F., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506110 · Cited by 772
HIV infection
Deeks, S. G., Overbaugh, J. M., Phillips, A. N., & Buchbinder, S. P. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.35 · Cited by 718
Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services.
Liu, A. Y., Cohen, S. E., Vittinghoff, E., Anderson, P. L., Doblecki-Lewis, S., Bacon, O., Chege, W., Postle, B. S., Matheson, T., Amico, K. R., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.4683 · Cited by 602
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial
Delany‐Moretlwe, S., Hughes, J. P., Bock, P., Ouma, S. G., Hunidzarira, P., Kalonji, D., Kayange, N., Makhema, J. M., Mandima, P., Mathew, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00538-4 · Cited by 609
Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women.
Nel, A., van Niekerk, N., Kapiga, S., Bekker, L.-G., Gama, C., Gill, K., Kamali, A., Kotze, P., Louw, C., Mabude, Z., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602046 · Cited by 479
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Molina, J.-M., Charreau, I., Spire, B., Cotte, L., Chas, J., Capitant, C., Tremblay, C., Rojas-Castro, D., Cua, E., Pasquet, A., et al. (2017) · The Lancet HIV · doi:10.1016/s2352-3018(17)30089-9 · Cited by 472
Clinical targeting of HIV capsid protein with a long-acting small molecule
Link, J. O., Rhee, M. S., Tse, W. C., Zheng, J., Somoza, J. R., Rowe, W., Begley, R., Chiu, A., Mulato, A. S., Hansen, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2443-1 · Cited by 447
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women
Klatt, N. R., Cheu, R., Birse, K., Zevin, A. S., Perner, M., Noël-Romas, L., Grobler, A., Westmacott, G., Xie, I. Y., Butler, J., et al. (2017) · Science · doi:10.1126/science.aai9383 · Cited by 428
Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy
Labovitz, D. L., Shafner, L., Reyes Gil, M., Virmani, D., & Hanina, A. (2017) · Stroke · doi:10.1161/strokeaha.116.016281 · Cited by 311
Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Curry, S. J., Doubeni, C. A., Epling, J. W., et al. (2019) · JAMA · doi:10.1001/jama.2019.6390 · Cited by 312
HIV
Ghosn, J., Taiwo, B., Seedat, S., Autran, B., & Katlama, C. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31311-4 · Cited by 332
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine
Cottrell, M. L., Yang, K. H., Prince, H. M. A., Sykes, C., White, N., Malone, S., Dellon, E. S., Madanick, R. D., Shaheen, N. J., Hudgens, M. G., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw077 · Cited by 312
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy
Anderson, P. L., Liu, A., Castillo‐Mancilla, J., Gardner, E. M., Seifert, S. M., McHugh, C., Wagner, T. M., Campbell, K. M., Morrow, M., Ibrahim, M. E., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01710-17 · Cited by 276
Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations
Murchú, É. Ó., Marshall, L., Hayes, C., Harrington, P., Moran, P., Teljeur, C., & Ryan, M. (2022) · BMJ Open · doi:10.1136/bmjopen-2020-048478 · Cited by 294
HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial
Deutsch, M. B., Glidden, D. V., Sevelius, J. M., Keatley, J. G., McMahan, V., Guanira, J. V., Kallas, E. G., Chariyalertsak, S., & Grant, R. M. (2015) · The Lancet HIV · doi:10.1016/s2352-3018(15)00206-4 · Cited by 283
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM
Hosek, S., Rudy, B. J., Landovitz, R. J., Kapogiannis, B. G., Siberry, G. K., Rutledge, B. N., Liu, N., Brothers, J., Mulligan, K. M., Zimet, G. D., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001179 · Cited by 275
Preexposure Prophylaxis for the Prevention of HIV Infection
Chou, R., Evans, C., Hoverman, A. S., Sun, C. J., Dana, T., Bougatsos, C., Grusing, S., & Korthuis, P. T. (2019) · JAMA · doi:10.1001/jama.2019.2591 · Cited by 275
HIV pre‐exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery
Celum, C., Delany‐Moretlwe, S., Baeten, J. M., van der Straten, A., Hosek, S., Bukusi, E. A., McConnell, M. A., Barnabas, R. V., & Bekker, L. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25298 · Cited by 265
HIV Preexposure Prophylaxis
Riddell, J., Amico, K. R., & Mayer, K. H. (2018) · JAMA · doi:10.1001/jama.2018.1917 · Cited by 265
Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review
Pleuhs, B., Quinn, K. G., Walsh, J. L., Petroll, A. E., & John, S. A. (2020) · AIDS Patient Care and STDs · doi:10.1089/apc.2019.0189 · Cited by 260
HIV infection
Bekker, L., Beyrer, C., Mgodi, N. M., Lewin, S. R., Delany‐Moretlwe, S., Taiwo, B., Masters, M. C., & Lazarus, J. V. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00452-3 · Cited by 289
HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans
Spinner, C. D., Boesecke, C., Zink, A., Jessen, H. K., Stellbrink, H., Rockstroh, J. K., & Eßer, S. (2015) · Infection · doi:10.1007/s15010-015-0850-2 · Cited by 253
A systematic review of adherence to oral pre-exposure prophylaxis for HIV – how can we improve uptake and adherence?
Sidebottom, D. B., Ekström, A. M., & Strömdahl, S. K. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3463-4 · Cited by 258
Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women
Goparaju, L., Praschan, N. C., Warren-Jeanpiere, L., Experton, L. S., Young, M., & Kassaye, S. (2017) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.1000730 · Cited by 227
Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis
Zhang, J., Li, C., Xu, J., Hu, Z., Rutstein, S. E., Tucker, J. D., Ong, J. J., Jiang, Y., Geng, W., Wright, S. T., et al. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(22)00030-3 · Cited by 238
Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy
Kirtane, A. R., Abouzid, O., Minahan, D., Bensel, T., Hill, A. L., Selinger, C., Bershteyn, A., Craig, M., Mo, S. S., Mazdiyasni, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02294-6 · Cited by 227
Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis
Tan, D. H. S., Hull, M., Yoong, D., Tremblay, C. L., O’Byrne, P., Thomas, R., Kille, J., Baril, J.-G., Cox, J., Giguère, P., et al. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.170494 · Cited by 221
Retention in care outcomes for HIV pre‐exposure prophylaxis implementation programmes among men who have sex with men in three US cities
Chan, P. A., Mena, L. A., Patel, R. R., Oldenburg, C. E., Beauchamps, L. S., Perez‐Brumer, A., Parker, S., Mayer, K. H., Mimiaga, M. J., & Nunn, A. S. (2016) · Journal of the International AIDS Society · doi:10.7448/ias.19.1.20903 · Cited by 226
The influence of HIV‐related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study
Velloza, J., Khoza, N., Scorgie, F., Chitukuta, M., Mutero, P., Mutiti, K. S., Mangxilana, N. T., Nobula, L., Bulterys, M. A., Atujuna, M., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25463 · Cited by 225
Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda
Baeten, J. M., Heffron, R. A., Kidoguchi, L., Mugo, N., Katabira, E. T., Bukusi, E. A., Asiimwe, S. B., Haberer, J. E., Morton, J. F., Ngure, K., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002099 · Cited by 217
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic
Namasivayam, V., Vanangamudi, M., Kramer, V. G., Kurup, S., Zhan, P., Liu, X., Kongsted, J., & Byrareddy, S. N. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00843 · Cited by 211
Sex Differences in HIV Infection
Scully, E. P. (2018) · Current HIV/AIDS Reports · doi:10.1007/s11904-018-0383-2 · Cited by 184
PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial
Celum, C., Hosek, S., Tsholwana, M., Kassim, S., Mukaka, S., Dye, B. J., Pathak, S., Mgodi, N. M., Bekker, L., Donnell, D. J., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003670 · Cited by 179
Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)
Hendrix, C. W., Andrade, A. S., Bumpus, N. N., Kashuba, A. D. M., Marzinke, M. A., Moore, A. T., Anderson, P. L., Bushman, L. R., Fuchs, E. J., Wiggins, I. P., et al. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0182 · Cited by 173
Current concepts for PrEP adherence in the PrEP revolution
Haberer, J. E. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000220 · Cited by 172
Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia
Bain, E., Shafner, L., Walling, D. P., Othman, A. A., Chuang‐Stein, C., Hinkle, J. E., & Hanina, A. (2017) · JMIR mhealth and uhealth · doi:10.2196/mhealth.7030 · Cited by 163
An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women
Balkus, J. E., Brown, E. R., Palanee‐Phillips, T., Nair, G., Gaffoor, Z., Zhang, J., Richardson, B. A., Chirenje, Z. M., Marrazzo, J. M., & Baeten, J. M. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000974 · Cited by 160
Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy
Cohen, M. S., & Chen, J. S. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25355 · Cited by 178
Rethinking HIV prevention to prepare for oral PrEP implementation for young African women
Celum, C., Delany‐Moretlwe, S., McConnell, M. A., van Rooyen, H., Bekker, L., Kurth, A., Bukusi, E. A., Desmond, C., Morton, J. F., & Baeten, J. M. (2015) · Journal of the International AIDS Society · doi:10.7448/ias.18.4.20227 · Cited by 156
The role of healthcare providers in the roll out of preexposure prophylaxis
Krakower, D., & Mayer, K. H. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000206 · Cited by 159
Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study
Liu, A., Vittinghoff, E., von Felten, P., Amico, K. R., Anderson, P. L., Lester, R. T., Andrew, E. V. W., Estes, I., Serrano, P. A., Brothers, J., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy810 · Cited by 157
A Gap Between Willingness and Uptake: Findings From Mixed Methods Research on HIV Prevention Among Black and Latina Transgender Women
Poteat, T., Wirtz, A. L., Malik, M., Cooney, E. E., Cannon, C. M., Hardy, W. D., Arrington‐Sanders, R., Lujan, M., & Yamanis, T. J. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002112 · Cited by 148
Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework
Amico, K. R., Wallace, M., Bekker, L., Roux, S., Atujuna, M., Sebastian, E., Dye, B. J., Elharrar, V., & Grant, R. M. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1458-y · Cited by 146
Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women
McKinnon, L. R., Liebenberg, L. J. P., Yende‐Zuma, N., Archary, D., Ngcapu, S., Sivro, A., Nagelkerke, N. J. D., Garcia-Lerma, J. G., Kashuba, A. D. M., Masson, L., et al. (2018) · Nature Medicine · doi:10.1038/nm.4506 · Cited by 152
Prevention, treatment and cure of HIV infection
Landovitz, R. J., Scott, H. M., & Deeks, S. G. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00914-1 · Cited by 151
Acyclovir resistance in herpes simplex viruses: Prevalence and therapeutic alternatives
Schalkwijk, H. H., Snoeck, R., & Andreï, G. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115322 · Cited by 151
Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa
Hosek, S., Celum, C., Wilson, C. M., Kapogiannis, B., Delany‐Moretlwe, S., & Bekker, L. (2016) · Journal of the International AIDS Society · doi:10.7448/ias.19.7.21107 · Cited by 138
Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions
Spinelli, M. A., Haberer, J. E., Chai, P. R., Castillo‐Mancilla, J., Anderson, P. L., & Gandhi, M. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00502-5 · Cited by 146
Acceptability and use of a dapivirine vaginal ring in a phase III trial
Montgomery, E., van der Straten, A., Chitukuta, M., Reddy, K., Woeber, K., Atujuna, M., Bekker, L., Etima, J., Nakyanzi, T., Mayo, A., et al. (2017) · AIDS · doi:10.1097/qad.0000000000001452 · Cited by 137
HIV epidemiology, prevention, treatment, and implementation strategies for public health
Mody, A., Sohn, A. H., Iwuji, C. C., Tan, R. K. J., Venter, F., & Geng, E. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01381-8 · Cited by 146
Recent advances in pre-exposure prophylaxis for HIV
Desai, M., Field, N. M., Grant, R. M., & McCormack, S. (2017) · BMJ · doi:10.1136/bmj.j5011 · Cited by 136
Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men
Greene, G. J., Swann, G., Fought, A. J., Carballo‐Diéguez, A., Hope, T. J., Kiser, P. F., Mustanski, B. S., & D’Aquila, R. T. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1565-9 · Cited by 127
Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients: A Randomized Clinical Trial (HPTN 065)
El-Sadr, W. M., Donnell, D., Beauchamp, G., Hall, H. I., Torian, L. V., Zingman, B., Lum, G., Kharfen, M., Elion, R., Leider, J., et al. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.2158 · Cited by 127
PrEP rollout in Africa: status and opportunity
Irungu, E., & Baeten, J. M. (2020) · Nature Medicine · doi:10.1038/s41591-020-0872-x · Cited by 134
Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial
Corneli, A. L., Perry, B., McKenna, K., Agot, K. E., Ahmed, K., Taylor, J., Malamatsho, F., Odhiambo, J. O., Skhosana, J., & Damme, L. V. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000880 · Cited by 127
Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women
Thomson, K. A., Baeten, J. M., Mugo, N., Bekker, L., Celum, C., & Heffron, R. A. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000207 · Cited by 117
Preexposure prophylaxis-related stigma: strategies to improve uptake and adherence – a narrative review
Haire, B. G. (2015) · HIV/AIDS - Research and Palliative Care · doi:10.2147/hiv.s72419 · Cited by 125
HPTN 068: A Randomized Control Trial of a Conditional Cash Transfer to Reduce HIV Infection in Young Women in South Africa—Study Design and Baseline Results
The HPTN 068 protocol team, Pettifor, A. E., MacPhail, C. L., Selin, A., Gómez-Olivé, F. X., Rosenberg, M. S., Wagner, R. G., Mabuza, W., Hughes, J. P., Suchindran, C., et al. (2016) · AIDS and Behavior · doi:10.1007/s10461-015-1270-0 · Cited by 116
Vaginal microbiota and susceptibility to HIV
Eastment, M. C., & McClelland, R. S. (2018) · AIDS · doi:10.1097/qad.0000000000001768 · Cited by 114
Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa
Nel, A. M., Bekker, L., Bukusi, E. A., Hellström, E., Kotze, P. L., Louw, C. E., Martinson, F. E. A., Masenga, G. G., Montgomery, E., Ndaba, N. D., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147743 · Cited by 113
Da evidência à ação: desafios do Sistema Único de Saúde para ofertar a profilaxia pré-exposição sexual (PrEP) ao HIV às pessoas em maior vulnerabilidade
Zucchi, E. M., Grangeiro, A., Ferraz, D., Pinheiro, T. F., Alencar, T., Ferguson, L., Estevam, D. L., & Munhoz, R. (2018) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00206617 · Cited by 130
Prevention of HIV in Adolescent Girls and Young Women: Key to an AIDS-Free Generation
Karim, Q. A., Baxter, C., & Birx, D. L. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001316 · Cited by 112
The Tablets, Ring, Injections as Options ( TRIO ) study: what young African women chose and used for future HIV and pregnancy prevention
van der Straten, A., Agot, K. E., Ahmed, K., Weinrib, R., Browne, E. N., Manenzhe, K. N., Owino, F., Schwartz, J. L., Minnis, A. M., & on behalf of the TRIO Study Team (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25094 · Cited by 109
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study
Baeten, J. M., Palanee‐Phillips, T., Mgodi, N. M., Mayo, A., Szydlo, D. W., Ramjee, G., Mirembe, B. G., Mhlanga, F., Hunidzarira, P., Mansoor, L. E., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(20)30304-0 · Cited by 110
Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa
Minnis, A. M., Browne, E. N., Boeri, M., Agot, K. E., van der Straten, A., Ahmed, K., Weinrib, R., Mansfield, C. A., & on behalf of the TRIO Study Team (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001945 · Cited by 108
Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection
Bekker, L., Rebe, K. B., Venter, F., Maartens, G., Moorhouse, M. A., Conradie, F., Wallis, C. L., Black, V., Harley, B., & Eakle, R. (2016) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v17i1.455 · Cited by 109
Pre-Exposure Prophylaxis: A Narrative Review of Provider Behavior and Interventions to Increase PrEP Implementation in Primary Care
Silapaswan, A., Krakower, D., & Mayer, K. H. (2016) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3899-4 · Cited by 109
HIV Prevention Interventions for Adolescents
Hosek, S., & Pettifor, A. E. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00431-y · Cited by 106
Microbicide vaginal rings: Technological challenges and clinical development
Malcolm, K. R., Boyd, P. J., McCoy, C. F., & Murphy, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.015 · Cited by 102
Declining and rebounding unhealthy alcohol consumption during the first year of HIV care in rural Uganda, using phosphatidylethanol to augment self‐report
Hahn, J. A., Emenyonu, N. I., Fatch, R., Muyindike, W. R., Kekiibina, A., Carrico, A. W., Woolf‐King, S., & Shiboski, S. (2016) · Addiction · doi:10.1111/add.13173 · Cited by 97
Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline
Coelho, L. E., Torres, T. S., Veloso, V. G., Landovitz, R. J., & Grinsztejn, B. G. J. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30238-3 · Cited by 101
A Risk Assessment Tool for Identifying Pregnant and Postpartum Women Who May Benefit From Preexposure Prophylaxis
Pintye, J. C., Drake, A. L., Kinuthia, J., Unger, J. B., Matemo, D. N., Heffron, R. A., Barnabas, R. V., Kohler, P. K., McClelland, R. S., & John-Stewart, G. C. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw850 · Cited by 99
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study
Nel, A. M., van Niekerk, N., Baelen, B. V., Malherbe, M., Mans, W., Carter, A., Steytler, J., van der Ryst, E., Craig, C., Louw, C. E., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(20)30300-3 · Cited by 99
Optimizing Pre-Exposure Antiretroviral Prophylaxis Adherence in Men Who Have Sex with Men: Results of a Pilot Randomized Controlled Trial of “Life-Steps for PrEP”
Mayer, K. H., Safren, S. A., Elsesser, S. A., Psaros, C., Tinsley, J. P., Marzinke, M. A., Clarke, W. A., Hendrix, C. W., Taylor, S. W., Haberer, J. E., et al. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1606-4 · Cited by 102
PrEP implementation research in Africa: what is new?
Cowan, F. M., Delany‐Moretlwe, S., Sanders, E. J., Mugo, N., Guédou, F. A., Alary, M., Béhanzin, L., Mugurungi, O. M., & Bekker, L. (2016) · Journal of the International AIDS Society · doi:10.7448/ias.19.7.21101 · Cited by 100
Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study
Moore, D. J., Jain, S., Dubé, M. P., Daar, E. S., Sun, X., Young, J., Corado, K., Ellorin, E. E., Milam, J. E., Collins, D. O., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix1055 · Cited by 100
Drug Resistance During HIV Pre-Exposure Prophylaxis
Gibas, K. M., van den Berg, P., Powell, V. E., & Krakower, D. (2019) · Drugs · doi:10.1007/s40265-019-01108-x · Cited by 105
Drug‐drug interactions between feminizing hormone therapy and pre‐exposure prophylaxis among transgender women: the iFACT study
Hiransuthikul, A., Janamnuaysook, R., Himmad, K., Kerr, S. J., Thammajaruk, N., Pankam, T., Phanjaroen, K., Mills, S., Vannakit, R., Phanuphak, P., et al. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25338 · Cited by 100
Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs
Cunha-Reis, C., Machado, A., Barreiros, L., Araújo, F., Nunes, R., Seabra, V., Ferreira, D., Segundo, M. A., Sarmento, B., & das Neves, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.020 · Cited by 95
Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.
Delany-Moretlwe, S., Lombard, C., Baron, D., Bekker, L.-G., Nkala, B., Ahmed, K., Sebe, M., Brumskine, W., Nchabeleng, M., Palanee-Philips, T., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30428-6 · Cited by 95
Integrating HIV Preexposure Prophylaxis With Community-Based Syringe Services for Women Who Inject Drugs: Results From the Project SHE Demonstration Study
Roth, A. M., Tran, N. K., Felsher, M. A., Gadegbeku, A. B., Piecara, B., Fox, R., Krakower, D., Bellamy, S. L., Amico, K. R., Benitez, J., et al. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002558 · Cited by 95
BHIVA/BASHH guidelines on the use of HIV pre–exposure prophylaxis (PrEP) 2018
Brady, M., Rodger, A., Asboe, D., Cambiano, V., Clutterbuck, D., Desai, M., Field, N. M., Harbottle, J., Jamal, Z., McCormack, S., et al. (2019) · HIV Medicine · doi:10.1111/hiv.12718 · Cited by 98
How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP
Pilkington, V., Hill, A. M., Hughes, S. L., Nwokolo, N. C., & Pozniak, A. (2018) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30312-5 · Cited by 94
Preexposure Prophylaxis for the Prevention of HIV
Chou, R., Spencer, H. C., Bougatsos, C., Blazina, I., Ahmed, A. Y., & Selph, S. (2023) · JAMA · doi:10.1001/jama.2023.9865 · Cited by 101
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials
Gilbert, P. B., Juraska, M., deCamp, A. C., Karuna, S., Edupuganti, S., Mgodi, N. M., Donnell, D. J., Bentley, C., Sista, N. D., Andrew, P., et al. (2017) · Statistical Communications in Infectious Diseases · doi:10.1515/scid-2016-0001 · Cited by 95
Tenofovir gel for the prevention of herpes simplex virus Type 2 infection.
Abdool Karim, S. S., Abdool Karim, Q., Kharsany, A. B. M., Baxter, C., Grobler, A. C., Werner, L., Kashuba, A., Mansoor, L. E., Samsunder, N., Mindel, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410649 · Cited by 92
Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence
Hanscom, B. S., Janes, H., Guarino, P., Huang, Y., Brown, E. R., Chen, Y. Q., Hammer, S. M., Gilbert, P. B., & Donnell, D. J. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001160 · Cited by 92
Predictors of HIV, HIV Risk Perception, and HIV Worry Among Adolescent Girls and Young Women in Lilongwe, Malawi
Price, J. T., Rosenberg, N. E., Vansia, D., Phanga, T., Bhushan, N. L., Maseko, B., Brar, S. K., Hosseinipour, M. C., Tang, J. H., Bekker, L., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001567 · Cited by 92
Provider perspectives on PrEP for adolescent girls and young women in Tanzania: The role of provider biases and quality of care
Pilgrim, N. A., Jani, N., Mathur, S., Kahabuka, C., Saria, V., Makyao, N., Apicella, L., & Pulerwitz, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196280 · Cited by 91
Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC)
Valgimigli, M., García‐García, H. M., Vrijens, B., Vranckx, P., McFadden, E. P., Costa, F., Pieper, K. S., Vock, D. M., Zhang, M., van Es, G., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy377 · Cited by 91
Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test
Gandhi, M., Bacchetti, P., Spinelli, M. A., Okochi, H., Baeten, J. M., Siriprakaisil, O., Klinbuayaem, V., Rodrigues, W. C., Wang, G., Vincent, M., et al. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001971 · Cited by 95
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study
Cohen, Y. Z., Butler, A. L., Millard, K. G., Witmer-Pack, M., Levin, R., Unson, C. G., Patel, R., Shimeliovich, I., Lorenzi, J. C. C., Horowitz, J. A., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219142 · Cited by 89
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077
Tolley, E. E., Zangeneh, S. Z., Chau, G., Eron, J., Grinsztejn, B. G. J., Humphries, H., Liu, A., Siegel, M., Maseko, B., Panchia, R., et al. (2020) · AIDS and Behavior · doi:10.1007/s10461-020-02808-2 · Cited by 92
A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis
Schlesinger, E. B., Johengen, D., Luecke, E. H., Rothrock, G. D., McGowan, I., van der Straten, A., & Desai, T. A. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1904-6 · Cited by 91

Authors: Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., Hendrix, C. W., Dai, J. Y., Ganesh, S., Mkhize, B., Taljaard, M., Parikh, U. M., Piper, J., Mâsse, B., Grossman, C., Rooney, J., Schwartz, J. L., Watts, H., Marzinke, M. A., Hillier, S. L., McGowan, I. M., & Chirenje, Z. M.
Affiliations: University of California, San Francisco (US)
Harborview Medical Center (US)
Family Health International 360 (US)
University of Zimbabwe (ZW)
Centre for the AIDS Programme of Research in South Africa (ZA)
University of Pittsburgh (US)
Johns Hopkins University (US)
South African Medical Research Council (ZA)
National Institutes of Health (US)
Eastern Virginia Medical School (US)
ORCID: Marrazzo, Jeanne M.
Richardson, Barbra A.
Gomez, Kailazarid
Mgodi, Nyaradzo
Nair, Gonasagrie
Nakabiito, Clemensia
Noguchi, Lisa
Hendrix, Craig W.
Dai, James Y.
Parikh, Urvi M.
Piper, Jeanna
Mâsse, Benoît
Rooney, James
Watts, Heather
Marzinke, Mark A.
Hillier, Sharon L.
McGowan, Ian M.
Chirenje, Z. Mike
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-02-05
Volume: 372
Issue: 6
Pages: 509-518
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1402269
PMC: PMC4341965
OpenAlex: W2044369525
Cited by: 1,296
References: 19
Citations by year: 2026: 32 · 2025: 54 · 2024: 59 · 2023: 78 · 2022: 93 · 2021: 143 · 2020: 125 · 2019: 139 · 2018: 122 · 2017: 140 · 2016: 175 · 2015: 131
FWCI: 147.62
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
ResearchSpace (University of KwaZulu-Natal) (submittedVersion)
Funders: National Institute of Allergy and Infectious Diseases (U01AI068633, UM1AI068615, UM1AI069422, UM1AI106707, UM1AI069436, P30AI094189, UM1AI069530, UM1AI069463, UM1AI069469)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: tenofovir disoproxil fumarate, tenofovir/emtricitabine, HIV pre-exposure prophylaxis, HIV-1 prevention, women, women of reproductive age, antiretroviral resistance, tenofovir resistance, drug safety, adverse events, creatinine elevation
MeSH terms: Emtricitabine, Tenofovir, Adenine, Administration, Intravaginal, Administration, Oral, Adolescent, Adult, Deoxycytidine, Drug Therapy, Combination, Female, HIV Seropositivity, Humans, Middle Aged, Surveys and Questionnaires, HIV-1, HIV Infections, Africa South of the Sahara, Drug Resistance, Viral, Anti-Retroviral Agents, Medication Adherence, Young Adult, Organophosphonates, Pre-Exposure Prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks